Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Millennium Pharmaceuticals Limited

Hiroshi Banno

Koji Ono

Toshio Tanaka

Takaharu Hirayama

Xin Liu

Takuto Kojima

Shinichi Imamura

Yoshiteru Ito

Hironobu Maezaki

Hidekazu Tokuhara

Keisuke Imamura

Yasuyoshi Arikawa

Masahiro Ito

Daisuke Tomita

Masaki Seto

Hiroyuki Tawada

Yasuhiro Hirata

Yasuhiro Imaeda

Satoshi Sasaki

Masaaki Mori

Hirokazu Matsumoto

Makoto Kamata

Norihito Tokunaga

Takahiko Taniguchi

Noriyuki Nii

Nobuki Sakauchi

Ryo Mizojiri

Moriteru Asano

Douglas Robert Cary

Youichi Kawakita

Osamu Kurasawa

Fumio Itoh

Jun Fujimoto

Zen-ichi Terashita

Michiko Tawada

Nobuo Cho

Akinori Toita

Hironori Kokubo

Tomoyasu Ishikawa

Nao Morishita

Masaki Kawamura

Keiji Kamiyama

Yuya Oguro

Nobuyuki Takakura

Masaaki Hirose

Shigemitsu Matsumoto

Yasutomi Asano

Terufumi Takagi

Mitsuhiro Ito

Shuji Kitamura

Shuhei Ikeda

Taku Kamei

Jinichi Yonemori

Naoki Tarui

Masanori Okaniwa

Takeshi Wakabayashi

Yutaka Nakayama

Krista E Gipson

Naoki Iwamura

Takuya Fujimoto

Kohji Fukatsu

Yuichiro Amano

Fumihiko Sato

Shuntarou Tsuchiya

Mayumi Imai

Hirotaka Kamitani

Takeshi Wakabaysahi

Shuntaro Tsuchiya

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

Heterocyclic compound and use thereof

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Provided is a compound represented by the following formula, or a salt thereof: 

Fused heterocyclic compound

Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

Bicyclic compound

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

Monocyclic compound

The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.

The present invention relates to a compound represented by the formula (I) or (I'): 

Thiazole derivatives

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

Fused heterocyclic ring derivative and use thereof

The present invention relates to a compound represented by the formula: wherein W is C(R) or N, each A is an optionally substituted aryl group or a heteroaryl group, Xis &#x2014;NR&#x2014;Y&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, &#x2014;SO&#x2014; or &#x2014;CHR&#x2014; wherein Ris a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or Ris optionally bonded to A to form an optionally substituted ring structure, Ris a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, Ris a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or Rand R, or Rand Rare optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

Bi- and tricyclic fused pyrimidines as tyrosine kinase inhibitors

The present invention provides a compound represented by the formula: 

Bicyclic piperazine compound having TGR23 antagonistic activity

Growing community of inventors

Kanagawa, Japan

Hiroshi Banno